Related Experiment Video

Updated: Aug 9, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Ras regulatory interactions: novel targets for anti-cancer intervention?

G C Prendergast1, J B Gibbs

  • 1Department of Cancer Research, Merck Research Laboratories, West Point, PA 19486.

Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology
|March 1, 1994
PubMed

Insights

Novel anti-cancer therapies targeting the Ras oncoprotein are emerging. Understanding upstream activators and downstream effectors of Ras signaling provides new avenues for developing effective anti-tumor interventions and chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ras oncoproteins are key regulators of cell signaling pathways.
  • Dysregulation of Ras signaling is implicated in various cancers.
  • Targeting Ras offers potential for anti-cancer drug development.

Purpose of the Study:

  • To review recent advances in understanding Ras oncoprotein function.
  • To identify novel intervention points for anti-tumor therapy.
  • To discuss potential applications in anti-cancer chemotherapy.

Main Methods:

  • Characterization of upstream regulators (guanine nucleotide exchange factors, adaptor proteins).
  • Analysis of downstream effectors (p120GAP, Raf kinase).
  • Review of biochemical interactions and functional requirements in oncogenic Ras signaling.

Main Results:

  • Identification of upstream factors linking Ras to growth factor receptor tyrosine kinases.
  • Elucidation of direct biochemical interactions of downstream effectors essential for Ras signaling.
  • Progress in understanding the molecular mechanisms of Ras oncogenic function.

Conclusions:

  • Advances in Ras biology provide new targets for cancer treatment.
  • Understanding upstream and downstream pathways is crucial for therapeutic strategies.
  • Novel applications for anti-cancer chemotherapy can be developed based on Ras pathway modulation.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.